CFO Alan Weichselbaum departs; Andriy Mushak appointed fractional CFO at $6K/month

Telomir Pharmaceuticals, Inc.

Alan Weichselbaum departs as CFO effective June 6, 2026; no disagreement cited.
Andriy Mushak, CPA, appointed fractional CFO effective June 6, 2026; will serve as independent contractor.
Mushak will receive $6,000 per month under a one-year consulting agreement with LMAM Consulting Group.
Mushak has 20+ years accounting experience; previously at Baker Tilly US, LLP and co-founded LMAM in 2025.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andriy Mushak

fractional Chief Financial Officer

TELO · Telomir Pharmaceuticals, Inc.

Effective: 2026-06-06
Filed: June 8, 2026, 5:00 PM ET

On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026

Departed

Alan Weichselbaum

Chief Financial Officer

TELO · Telomir Pharmaceuticals, Inc.

Effective: 2026-06-06
Successor: Andriy Mushak
Filed: June 8, 2026, 5:00 PM ET

Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the "Company"). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andriy Mushak was appointed as fractional Chief Financial Officer at Telomir Pharmaceuticals, Inc..

Action: appointed
Role: fractional Chief Financial Officer

Exact text from the filing

On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan Weichselbaum departed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..

Action: will be no longer serving
Role: Chief Financial Officer

Exact text from the filing

Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the "Company"). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

View on SEC.gov

Telomir Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-027752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.